Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment

Stock Track

Feb 12

NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.

The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.

The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1158168445"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158168445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158168445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158168445","market":"nz","top_or_hot":-1,"title":"Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment","media":"Stock Track","content":"<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1158168445","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158168445","pubTimestamp":1770889594,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"个股追踪|NovoCure上市前暴涨26.67%获FDA批准治疗胰腺癌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}